MOLECULIN BIOTECH INC

New Annamycin data unveiled at AACR and European meetings, spotlighting its topoisomerase‑II action and early AML trial promise for Moleculin Biotech’s next‑gen cancer therapy.

Explore how Moleculin Biotech’s $9.3 m public offering fuels its Annamycin anti‑cancer program and advances skin disease treatments.

Discover how Houston‑based Moleculin Biotech is advancing anti‑cancer drug candidates and skin disease treatments, with a growing Nasdaq portfolio and breakthrough research.

Executive stock‑buybacks at Moleculin Biotech signal confidence in its anti‑cancer R&D, showing leadership’s belief in future growth and innovation.

Explore Moleculin Biotech’s journey developing anti‑cancer therapies, stock trends, and pipeline potential for investors and patients seeking innovative oncology solutions.

Discover Moleculin Biotech’s Phase 3 Annamycin AML trial: key safety, efficacy data, and a new patent announced ahead of its Madrid presentation.

Moleculin Biotech, Inc. is a pioneering pharmaceutical company developing innovative anti-cancer therapies and treatments, offering hope to patients and a beacon of resilience in the biotechnology sector.

Moleculin Biotech, Inc. is a pioneering pharmaceutical company developing innovative anti-cancer therapies and treatments for skin diseases, offering new hope for patients and shaping the future of cancer care.

Moleculin Biotech Inc faces significant financial and operational challenges, raising concerns about its future trajectory in the biotechnology sector.

Moleculin Biotech Inc. has received approval to expand its clinical trial in Georgia, increasing the number of sites from 14 to over 30, in a pivotal study for its Annamycin-based treatment for relapsed/refractory acute myeloid leukemia.